QNRX (Quoin Pharmaceuticals, Ltd. American Depositary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by QNRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-06 | MICHAEL T SEMBER | Director | A | — | — |
| 2026-02-06 | DENNIS LANGER | Director | A | — | — |
| 2026-02-06 | Anthony James Culverwell | Director | A | — | — |
| 2026-02-06 | Denise P. Carter | Chief Operating Officer | A | — | — |
| 2026-02-06 | Michael Myers | Chief Executive Officer | A | — | — |
| 2026-02-06 | Natalie Ee Mun Leong | Director | A | — | — |
| 2026-02-06 | Joseph Patrick Cooper | Director | A | — | — |
| 2026-02-06 | Sally Bridget Lawlor | Chief Financial Officer | A | — | — |
| 2025-12-03 | Sally Bridget Lawlor | Chief Financial Officer | A | — | — |
| 2025-10-15 | DENNIS LANGER | Director | Buy | — | — |
| 2025-08-25 | Anthony James Culverwell | Director | A | — | — |
| 2025-08-25 | DENNIS LANGER | Director | A | — | — |
| 2025-08-25 | Natalie Ee Mun Leong | Director | A | — | — |
| 2025-06-13 | Denise P. Carter | Chief Operating Officer | A | — | — |
| 2025-06-13 | Michael Myers | Chief Executive Officer | A | — | — |
| 2025-06-03 | Anthony James Culverwell | Director | A | — | — |
| 2025-06-02 | MICHAEL T SEMBER | Director | A | — | — |
| 2025-06-02 | Natalie Ee Mun Leong | Director | A | — | — |
| 2025-06-02 | DENNIS LANGER | Director | A | — | — |
| 2025-06-02 | Joseph Patrick Cooper | Director | A | — | — |
| 2025-06-02 | Michael Myers | Chief Executive Officer | A | — | — |
| 2025-06-02 | Denise P. Carter | Chief Operating Officer | A | — | — |
| 2024-12-27 | Gordon Dunn | Chief Financial Officer | Buy | — | — |
| 2024-12-27 | Denise P. Carter | Chief Operating Officer | Buy | — | — |
| 2024-12-27 | Michael Myers | Chief Executive Officer | Buy | — | — |
| 2024-12-27 | Anthony James Culverwell | Director | Buy | — | — |
| 2024-12-10 | DENNIS LANGER | Director | A | — | — |
| 2024-12-10 | Denise P. Carter | Chief Operating Officer | A | — | — |
| 2024-12-10 | Anthony James Culverwell | Director | A | — | — |
| 2024-12-10 | Michael Myers | Chief Executive Officer | A | — | — |
| 2024-12-10 | Gordon Dunn | Chief Financial Officer | A | — | — |
| 2024-12-10 | Joseph Patrick Cooper | Director | A | — | — |
| 2024-12-10 | MICHAEL T SEMBER | Director | A | — | — |
| 2024-12-10 | Natalie Ee Mun Leong | Director | A | — | — |
| 2024-09-11 | Gordon Dunn | Chief Financial Officer | Buy | — | — |
| 2024-09-05 | Denise P. Carter | Chief Operating Officer | Buy | — | — |
| 2024-09-05 | Michael Myers | Chief Executive Officer | Buy | — | — |
| 2024-06-10 | DENNIS LANGER | Director | Sell | — | — |
| 2023-10-30 | Anthony James Culverwell | Director | A | — | — |
| 2023-10-30 | Michael Myers | Chief Executive Officer | A | — | — |
| 2023-10-30 | Natalie Ee Mun Leong | Director | A | — | — |
| 2023-10-30 | DENNIS LANGER | Director | A | — | — |
| 2023-10-30 | Denise P. Carter | Chief Operating Officer | A | — | — |
| 2023-10-30 | Joseph Patrick Cooper | Director | A | — | — |
| 2023-10-30 | Gordon Dunn | Chief Financial Officer | A | — | — |
| 2023-10-30 | MICHAEL T SEMBER | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 17,223 | — |
| — | Chief Operating Officer | 17,219 | — |
| — | Director | 15,153 | — |
| — | Chief Financial Officer | 4,316 | — |
| — | Director | 2,866 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the QNRX quote page; the site-wide leaderboard is on the insider transactions hub.